Drug Type Antibody drug conjugate (ADC)  | 
Synonyms BL-M05D1  | 
Target  | 
Action inhibitors  | 
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)  | 
Therapeutic Areas  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePhase 1  | 
First Approval Date-  | 
Regulation-  | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Adenocarcinoma of Esophagus | Phase 1 | United States   | 30 Jul 2025 | |
| Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | United States   | 30 Jul 2025 | |
| Biliary Tract Neoplasms | Phase 1 | United States   | 30 Jul 2025 | |
| Metastatic Solid Tumor | Phase 1 | United States   | 30 Jul 2025 | |
| stomach adenocarcinoma | Phase 1 | United States   | 30 Jul 2025 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China   | 19 Apr 2024 | 






